(DMAC) – Management Comments
-
DiaMedica Therapeutics Inc. (DMAC) Reports 'Successful' Type B Meeting with FDA for Study of DM199
-
DiaMedica Therapeutics Inc. (DMAC) Reports First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study
-
-
-
-
Back to DMAC Stock Lookup